Biotech developing a prophylactic vaccine against Group B Streptococcus (GBS).
| Date | Round | Amount |
|---|---|---|
| Oct 2023 | Funding round Danish biotech MinervaX raised an upsized EUR54M financing, with EQT Life Sciences and OrbiMed, to advance its Group B Streptococcus vaccine toward Phase III. | $58M |
| Dec 2022 | Funding round Copenhagen biotech MinervaX raised EUR22M in equity, co-led by Trill Impact Ventures and Pureos Bioventures, to advance its Group B Streptococcus vaccine toward Phase 3. | $23.3M |
| Dec 2022 | Debt MinervaX secured a debt facility of up to EUR50M from the European Investment Bank alongside its equity round. | $53M |